1. Rao VN et al. J Am Coll Cardiol. 2021;78(20):2004-2012.

2. Greene SJ et al. JAMA Cardiol. 2021;6(7):743-744.

3. Krum H et al. JAMA. 2003;289(6):712-718.

4. Zannad F et al. N Engl J Med. 2011;364(1):11-21.

5. Morrow DA et al. Circulation. 2019;139(19):2285-2288.

6. Berg DD et al. JAMA Cardiol. 2021;6(5):499-507.

7. Jhund PS et al. Eur Heart J. 2015;36(38):2576-2584.

8. Japp D et al. Age Ageing. 2017;46(1):18-25.

9. Kotecha D et al. BMJ. 2016;353:i1855.

10. Martinez FA et al. Circulation. 2020;141(2):100-111.

11. Butt JH et al. Ann Intern Med. 2022:175(6):820-830.

12. Mebazaa A et al. Lancet. 2022;400(10367):1938-1952.

ACM, any-cause mortality
ACEi, angiotensin-converting enzyme inhibitor
ARNi, angiotensin receptor-neprilysin inhibitor
BMI, body mass index
BNP, B-type natriuretic peptide
CI, confidence interval
CV, cardiovascular
ECG, echocardiogram
EF, ejection fraction
eGFR, estimated glomerular filtration rate
GDMT, guideline-directed medical therapy
HF, heart failure
HFA, Heart Failure Association
HFpEF, heart failure with preserved ejection fraction
HFrEF, heart failure with reduced ejection fraction
HHF, hospitalization for heart failure
HR, hazard ratio
LVEF, left-ventricular ejection fraction
MEN2, multiple endocrine neoplasia type 2
MI, myocardial infarction
MRA, mineralocorticoid receptor antagonist
MTC, medullary thyroid carcinoma
NP, natriuretic peptide
NSTEMI, non-ST-segment elevation myocardial infarction
NT-proBNP, N-terminal pro B-type natriuretic peptide
NYHA, New York Heart Association
RR, relative risk/risk ratio
RRR, relative risk reduction
RWE, real-world evidence
SAE, serious adverse event
SBP, systolic blood pressure
sCr, serum creatinine
SGLT2i, sodium-glucose cotransporter 2 inhibitor
SoC, standard of care
STEMI, ST-segment elevation myocardial infarction
T1D, type 1 diabetes
T1DM, type 1 diabetes mellitus
T2DM, type 2 diabetes mellitus
TR, tricuspid regurgitation
Y, year